Video Transcript

Tommy Sternberg, CFA, Partner
Research Analyst, Global Equity Team

Hi. This is Tommy Sternberg, coming to you from Tokyo, where I just finished a week of meetings with about a dozen healthcare companies. I met with several leading companies from the pharmaceutical industry as well as medical devices. First time back to Tokyo in several years. It’s great to be doing meetings live in person.

  • Insight #1 Japan is a hotbed for drug development, with strength in oncology, neurology and rare diseases
  • Insight #2 Out-licensing remains a primary source of monetization, but companies are increasingly retaining global rights
  • Insight #3 A selective approach to investing in Japanese pharma is key as opportunities can present themselves

You really get a good feel for what’s going on at these companies, especially when you meet with several of them over the course of a week, in person. You really can tell who’s excited about their products and generate interesting insights that I think otherwise would be really hard to come by. So it’s one of the best parts about this job, traveling to these places. 


The views and opinions expressed herein are those of the speaker(s) as of the date of publication, are subject to change without notice as economic and market conditions dictate, and may not reflect the views and opinions of other investment teams within William Blair. Factual information has been obtained from sources we believe to be reliable, but its accuracy, completeness, or interpretation cannot be guaranteed. This material may include estimates, outlooks, projections, and other forward-looking statements. Due to a variety of factors, actual events may differ significantly from those presented. This video has been provided for informational purposes only and should not be considered as investment advice or a recommendation of any particular strategy or investment product, or as an offer to buy or sell any securities or related financial instruments in any jurisdiction. Investment advice and recommendations can be provided only after careful consideration of an investor’s objectives, guidelines, and restrictions. Investing involves risks, including the possible loss of principal. Past performance is not indicative of future results.